Compare Quest Diagnostics Inc (DGX) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs InMode Ltd — how do they compare? Quest Diagnostics Inc trades at $237.47 (market cap $26.21B), while InMode Ltd trades at $15.24 (market cap $872.08M). The key difference: Quest Diagnostics Inc is far larger — about 30.1× InMode Ltd's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| DGX | INMD | |
|---|---|---|
Market Cap | $26.21B | $872.08M |
Sector | Health | Technology |
52-Week High | $238.50 | $16.62 |
52-Week Low | $173.49 | $12.76 |
Enterprise Value | $31.97B | $375.42M |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
INMD trades at $15.24, up 0.33% on the day, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company maintains strong profitability with a 20.69% net income margin and attractive valuation ratios, including a P/E of 12.52. Recent news highlights include Q2 2026 results consistent with the prior year and an unsolicited acquisition proposal from Steel Partners at $16.75 per share.
The stock presents a value opportunity given its low valuation multiples and high margins, but faces near-term uncertainty from shareholder activism, a securities fraud investigation, and potential acquisition volatility. Analyst sentiment is divided between Buy and Hold ratings, reflecting the balance between fundamental strength and corporate governance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
